Ratings JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Delayed Japan Exchange Other stock markets 08:57:34 2024-05-06 pm EDT			5-day change	1st Jan Change
807 ^JPY	+0.12%		-0.98%	-31.14%

Apr. 25	JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024	CI
Mar. 21	US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JCR PHARMACEUTICALS CO., LTD.	-31.14%	658M	-
ELI LILLY AND COMPANY	+31.52%	662B	C+
NOVO NORDISK A/S	+21.96%	546B	B
JOHNSON & JOHNSON	-5.21%	359B	C+
MERCK & CO., INC.	+17.02%	323B	B-
ABBVIE INC.	+5.01%	289B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+3.81%	198B	B-
ROCHE HOLDING AG	-10.63%	194B	A+
AMGEN INC.	+3.98%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes